FDA approves First RSV vaccine for adults under 60

FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine's rollout,
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.
FDA approves 1st RSV vaccine for adults under 60
The expansion builds on the previous indication for adults 60 years and older. The vaccine is also approved for pregnant individuals to protect infants from birth up to six months. With the decision,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
Seniors Shielded: New RSV Vaccine Shows 80% Effectiveness
Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...
MLive10h
What parents of young children should know about RSV, including ‘new armor’
Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
WGNO-TV New Orleans on MSN18h
Vaccine against flu, COVID, and RSV
The Centers for Disease Control and Prevention and the New Orleans Health Department encourage residents to vaccine against ...
psychiatryadvisor.com17h
RSV Vaccine Is Recommended for Long-Term Care Facility Residents
The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
WZZM on MSN2d
Experts encourage pregnant women to get the RSV vaccine before cases begin to rise
Which is why doctors and health experts are encouraging people to get the RSV vaccine now. That includes. Dr. Eryn Hart ...
Doctors urge families to protect babies, older adults as RSV immunizations now in supply: HealthLink
Expecting mothers in their 32nd to 36th week of pregnancy can get an RSV vaccine, which will pass along antibodies to their newborn. Or, babies up to eight months old, can get a monoclonal antibody ...